Saba N - Search Results

1

Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.

Kauh J, Chanel-Vos C, Escuin D, Fanucchi MP, Harvey RD, Saba N, Shin DM, Gal A, Pan L, Kutner M, Ramalingam SS, Bender L, Marcus A, Giannakakou P, Khuri FR. Kauh J, et al. Among authors: saba n. Cancer. 2011 Sep 1;117(17):4049-59. doi: 10.1002/cncr.26004. Epub 2011 Mar 1. Cancer. 2011. PMID: 21365629 Free PMC article. Clinical Trial.

2

Novel targeted agents in the treatment of lung cancer.

Saba N, Khuri F. Saba N, et al. Expert Opin Investig Drugs. 2004 Jun;13(6):609-29. doi: 10.1517/13543784.13.6.609. Expert Opin Investig Drugs. 2004. PMID: 15174948 Review.

3

Chemoprevention in lung cancer.

Saba N, Jain S, Khuri F. Saba N, et al. Curr Probl Cancer. 2004 Sep-Oct;28(5):287-306. doi: 10.1016/j.currproblcancer.2004.05.005. Curr Probl Cancer. 2004. PMID: 15375805 Review. No abstract available.

4

The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.

Saba N, Khuri F. Saba N, et al. Oncology. 2005;68(1):10-7. doi: 10.1159/000084517. Epub 2004 Mar 15. Oncology. 2005. PMID: 15775688 Review.

5

The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses.

Saba N, Khuri F. Saba N, et al. Oncology. 2005;68(1):18-22. doi: 10.1159/000084518. Epub 2005 Mar 15. Oncology. 2005. PMID: 15775689 Review.

6

Chemoprevention strategies for patients with lung cancer in the context of screening.

Saba NF, Khuri FR. Saba NF, et al. Clin Lung Cancer. 2005 Sep;7(2):92-9. doi: 10.3816/CLC.2005.n.023. Clin Lung Cancer. 2005. PMID: 16179095 Review.

7

Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.

Saba NF, Khuri FR, Shin DM. Saba NF, et al. Oncology (Williston Park). 2006 Feb;20(2):153-61; discussion 162, 166, 169 passim. Oncology (Williston Park). 2006. PMID: 16562649 Review.

8

Moving toward bioadjuvant approaches to head and neck cancer prevention.

Saba NF, Hammond A, Shin DM, Khuri FR. Saba NF, et al. Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S132-5. doi: 10.1016/j.ijrobp.2007.05.041. Int J Radiat Oncol Biol Phys. 2007. PMID: 17848282 Review.

9

Targeting angiogenesis in head and neck cancer.

Saba NF, Shin DM, Khuri FR. Saba NF, et al. Curr Cancer Drug Targets. 2007 Nov;7(7):643-9. doi: 10.2174/156800907782418356. Curr Cancer Drug Targets. 2007. PMID: 18045069 Review.

10

Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation.

Muller S, Su L, Tighiouart M, Saba N, Zhang H, Shin DM, Chen Z. Muller S, et al. Among authors: saba n. Cancer. 2008 Jul 1;113(1):97-107. doi: 10.1002/cncr.23557. Cancer. 2008. PMID: 18473353 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

513 results

Search Page

Filters